Fosamax | The American Association For Justice

Fosamax

Description:

The primary focus of this Litigation Group is on Fosamax®. However, the group also intends to cover other Bisphosphonate drugs (e.g. Aredia, Zometa).

Fosamax® (Alendronate) is a compound that alters the cycle of bone formation and breakdown in the body. Fosamax® is manufactured by Merck & Co. In December 2004 doctors at Long Island Jewish Medical Center (LIJ) announced that they had discovered a link between bisphosphonate drugs and osteonecrosis of the jaw (ONJ), or literally, death of the jaw bone tissue. The report prompted both the U.S. Food and Drug Administration (FDA) and bisphosphonate drug makers to issue updated warnings to doctors. Merck stated it received a request from the FDA to update the label in January 2005. There is currrently an MDL in S.D. NY (MDL 1789) and there is expected to be significant litigation in State Court in New Jersey.

Background:

Formed February 2007.

Benefits & Resources:

The Fosamax® Litigation Group has a list server and Document Library where members can share information, documents, and pertinent information.

Meetings:

AAJ Annual and Winter Conventions, or as needed by group members.

Membership:
Open to Regular, Sustaining, Life, Leaders Forum, and President's Club members.
Cochairs:

Richard A. Gurfein
Gurfein Douglas LLP
11 Park Pl., Suite 705
New York, NY 10007
Phone: 212/406-1600
Fax: 212/406-4779
rgurfein@gurfeindouglas.com

David B. Rheingold
Rheingold, Valet, Rheingold, McCartney & Giuffra LLP
113 E. 37th St.
New York, NY 10016
Phone: 212/684-1880
Fax: 212/689-8156
drheingold@rheingoldlaw.com

Dues:
$300/first two attorneys, $100/additional member